RxDoctor Payments Data

Kellye Garrett

Psychiatric/Mental Health · Booneville, MSNPI 1184844466

Payments from drug & device makers

$2,151in general payments, 2019–2025

Across 172 payments — averaging $12.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$566
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$386
  • AbbVie$306
  • Vanda Pharmaceuticals Inc.$208
  • Otsuka America Pharmaceutical, Inc.$184
  • Teva Pharmaceuticals USA, Inc.$173
  • plus $329 from 5 others

What the payments were for

  • Food & beverage$1,99393%
  • Education$1587%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,151 in reported general payments places this provider in the 75th percentile of 486 psychiatric/mental health providers in Mississippi.

See all psychiatric/mental health providers in Mississippi

Medicare billing

Part B allowed, 2024
$16,780
Medicare patients
115
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate96$303,337
Invega TrinzaPaliperidone Palmitate19$172,761
AustedoDeutetrabenazine19$137,186
VraylarCariprazine Hcl61$91,805
Abilify MaintenaAripiprazole19$48,255
FanaptIloperidone19$44,415
CaplytaLumateperone Tosylate22$39,308
RexultiBrexpiprazole17$24,429
Risperdal ConstaRisperidone Microspheres13$22,535
TrintellixVortioxetine Hydrobromide27$13,079
Quetiapine Fumarate307$7,816
Aripiprazole207$5,562
Lurasidone Hcl23$5,548
VyvanseLisdexamfetamine Dimesylate12$4,820
Chlorpromazine Hcl69$4,732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$566$498,632128 claims
Teva Pharmaceuticals USA, Inc.Austedo$173$137,18619 claims
AbbVieVraylar$306$91,80561 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$184$72,68436 claims
Vanda Pharmaceuticals Inc.Fanapt$208$44,41519 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$386$39,30822 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$109$17,89939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 486 psychiatric/mental health providers in Mississippi.

Other psychiatric/mental health in Booneville

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →